Abeona Therapeutics Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; comparisons are with fiscal 2021. This is an annual filing, not a quarterly report. Abeona is a clinical-stage biopharmaceutical company with no approved products and limited operating revenue.
Business context and progress
- EB-101: The lead autologous cell-therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB). In November 2022, Abeona reported that the Phase 3 VIITAL study met both co-primary endpoints for wound healing and pain reduction. The study evaluated 43 wound pairs in 11 subjects. No serious treatment-related adverse events were reported in the topline results.
- Management planned to submit an EB-101 Biologics License Application (BLA) to the FDA in late Q2 or early Q3 2023. EB-101 has FDA RMAT, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; these designations do not assure approval.
- Abeona licensed ABO-102 for MPS IIIA to Ultragenyx in May 2022, which assumed development, manufacturing and commercialization responsibilities. Abeona discontinued ABO-101 for MPS IIIB and prioritized EB-101. ABO-503, ABO-504 and ABO-505 remained preclinical ophthalmic gene-therapy programs.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| License and other revenue | $1.4 million | $3.0 million |
| Research and development expense | $29.0 million | $38.7 million |
| General and administrative expense | $17.3 million | $21.6 million |
| Operating loss | $50.9 million | $89.8 million |
| Net loss | $39.7 million | $84.9 million |
| Cash used in operating activities | $43.5 million | $65.7 million |
- Revenue was primarily from a Taysha milestone and other license-related items. The company reported no significant product-sales revenue.
- At December 31, 2022, cash, cash equivalents, restricted cash and short-term investments totaled $52.5 million. Current assets were $53.1 million and current liabilities were $7.8 million.
- Total liabilities were $37.5 million, including $19.7 million of warrant liabilities, $7.6 million of lease liabilities and $4.2 million payable to REGENXBIO. The filing does not indicate conventional outstanding bank debt; the warrant liability is a fair-value accounting obligation.
- Management said available resources were expected to fund operations for at least 12 months from the filing date, while noting additional capital may be needed. Profitability and meaningful product revenue are not assured.
- Cash from financing activities was $43.2 million, including net proceeds from ATM stock sales and a private placement. Common shares outstanding increased substantially during 2022; the company also had 9.4 million warrants outstanding at year-end.
Material changes and unusual items
- R&D expense declined 25%, primarily reflecting reduced work on the MPS programs, lower stock compensation and lower personnel costs. G&A expense declined 20%, primarily due to lower professional fees and stock compensation.
- FY 2022 net loss included $5.7 million of impairment charges: $1.4 million for licensed technology, $2.5 million for lease assets and $1.8 million for construction-in-progress, largely associated with the shift away from ABO-101/ABO-102-related facilities and assets. FY 2021 included a $32.5 million goodwill impairment.
- A $11.4 million noncash gain from the change in fair value of warrant liabilities reduced the 2022 net loss. FY 2021 included a $6.7 million gain on settlement with REGENXBIO and $1.8 million of PPP loan forgiveness income; neither recurred in 2022.
- In 2022, the company raised $22.5 million net through convertible redeemable preferred stock, which holders subsequently required Abeona to redeem for $26.3 million. The transaction resulted in $3.8 million of deemed dividends attributable to common shareholders.
- Abeona disclosed an accounting correction for 2021 warrants: liabilities and additional paid-in capital were each adjusted by $9.0 million in the restated 2021 balance sheet. The filing says the error was not material to previously issued financial statements and did not affect the 2021 statement of operations.
- The company effected a 1-for-25 reverse stock split on July 1, 2022. Per-share and share-count data in the filing are adjusted for the split unless otherwise stated.
Outlook, risks and contingencies
- The principal near-term catalyst was the planned EB-101 BLA submission. Timing and outcome depend on FDA review, clinical-data sufficiency, manufacturing readiness and regulatory inspection; approval and commercialization are uncertain.
- Abeona relies on financing, licensing and potential partnerships to support development. Future equity financing could dilute shareholders; failure to secure funding could require further spending reductions or program delays.
- Manufacturing is a key risk: EB-101 is patient-specific, and the company reported no backup manufacturer for clinical supply. Production failures, quality issues or regulatory noncompliance could delay development or commercialization.
- Other material risks include clinical or regulatory setbacks, competition, reimbursement and market acceptance, intellectual-property and licensing matters, reliance on third parties, and the ability to retain key personnel.
- Under its REGENXBIO settlement, Abeona had a remaining $5.0 million payment due in November 2024 or earlier upon a defined strategic transaction. Management reported no material pending legal proceedings at year-end.
- The independent auditor gave an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not required to attest to internal-control effectiveness.
Key facts investors should verify
- Whether and when the EB-101 BLA was submitted, accepted for review and acted upon by the FDA, and whether any additional data or manufacturing work was requested.
- Current cash resources, operating cash burn and financing needs relative to management’s stated runway; also consider the potential dilution and exercise terms of outstanding warrants and ATM capacity.
- Progress and economics of the Ultragenyx ABO-102 license, including any development milestones, royalties or commercial payments actually earned.
- Whether the VIITAL trial’s full data and safety profile support the BLA and prospective commercial use, beyond the topline results summarized in this filing.
- The remaining REGENXBIO payment, lease obligations and any subsequent material changes to liabilities, programs or financing arrangements.